NASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis $25.74 +0.96 (+3.87%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$25.58 -0.15 (-0.60%) As of 08/22/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ACADIA Pharmaceuticals alerts:Sign Up Key Stats Today's Range$24.90▼$25.8150-Day Range$20.88▼$25.7452-Week Range$13.40▼$25.88Volume3.42 million shsAverage Volume1.84 million shsMarket Capitalization$4.34 billionP/E Ratio19.35Dividend YieldN/APrice Target$28.88Consensus RatingModerate Buy Company Overview ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. Read More ACADIA Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreACAD MarketRank™: ACADIA Pharmaceuticals scored higher than 77% of companies evaluated by MarketBeat, and ranked 225th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.61, and is based on 10 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ACADIA Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.57% Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 8.57% in the coming year, from $0.70 to $0.76 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is 19.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.40.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is 19.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 31.10.Price to Earnings Growth RatioACADIA Pharmaceuticals has a PEG Ratio of 6.31. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ACADIA Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.89% of the float of ACADIA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 3.92%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.89% of the float of ACADIA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 3.92%, indicating that investor sentiment is improving. News and Social Media2.2 / 5News Sentiment0.94 News SentimentACADIA Pharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for ACADIA Pharmaceuticals this week, compared to 10 articles on an average week.Search InterestOnly 4 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $868,594.00 in company stock.Percentage Held by Insiders26.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ACADIA Pharmaceuticals' insider trading history. Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Stock News HeadlinesMark Schneyer Sells 22,000 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) StockAugust 20 at 5:41 AM | insidertrades.comSaniona and Jazz Pharmaceuticals Ink Licensing Deal for Epilepsy TreatmentAugust 20 at 3:18 PM | msn.comThe Secret E.I. Project No One’s Talking About… YetIt took Netflix 3.5 years to reach 1 million users. Twitter? Two years. Facebook? Ten months. ChatGPT? Just 5 days. Now, the next evolution of AI is coming—and it’s happening fast. Known as embodied intelligence (E.I.), this breakthrough merges AI with robotics to create advanced machines: from robot caregivers to autonomous soldiers. Top researchers from around the globe are quietly collaborating on a massive E.I. project set to launch within 90 days.August 23 at 2:00 AM | Behind the Markets (Ad)Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $28.88August 18, 2025 | americanbankingnews.comHigh Growth Tech Stocks To Watch In The US August 2025August 15, 2025 | uk.finance.yahoo.comShareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full StoryAugust 14, 2025 | finance.yahoo.comAnalysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), AMN Healthcare Services (AMN)August 13, 2025 | theglobeandmail.comNeedham Keeps Their Buy Rating on Avadel Pharmaceuticals (AVDL)August 12, 2025 | theglobeandmail.comSee More Headlines ACAD Stock Analysis - Frequently Asked Questions How have ACAD shares performed this year? ACADIA Pharmaceuticals' stock was trading at $18.35 at the beginning of the year. Since then, ACAD shares have increased by 40.3% and is now trading at $25.74. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its earnings results on Wednesday, August, 6th. The biopharmaceutical company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.14 by $0.02. The company's revenue was up 9.4% compared to the same quarter last year. Read the conference call transcript. Who are ACADIA Pharmaceuticals' major shareholders? Top institutional shareholders of ACADIA Pharmaceuticals include State Street Corp (3.66%), Geode Capital Management LLC (1.81%), First Trust Advisors LP (1.44%) and Marshall Wace LLP (1.17%). Insiders that own company stock include Bros Advisors Lp Baker, Stephen Davis, Brendan Teehan, Srdjan R Stankovic, Austin D Kim, Mark C Schneyer, James Kihara, Elizabeth A Garofalo and Laura Brege. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY). Company Calendar Last Earnings8/06/2025Today8/22/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACAD CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees510Year FoundedN/APrice Target and Rating Average Price Target for ACADIA Pharmaceuticals$28.88 High Price Target$40.00 Low Price Target$17.00 Potential Upside/Downside+12.2%Consensus RatingModerate Buy Rating Score (0-4)2.61 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)$1.33 Trailing P/E Ratio19.35 Forward P/E Ratio36.77 P/E Growth6.31Net Income$226.45 million Net Margins21.80% Pretax Margin26.29% Return on Equity14.69% Return on Assets9.41% Debt Debt-to-Equity RatioN/A Current Ratio2.91 Quick Ratio2.83 Sales & Book Value Annual Sales$957.80 million Price / Sales4.53 Cash Flow$0.73 per share Price / Cash Flow35.16 Book Value$4.87 per share Price / Book5.29Miscellaneous Outstanding Shares168,710,000Free Float124,003,000Market Cap$4.34 billion OptionableOptionable Beta0.70 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ACAD) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.